合成目标产物 Loratadine 主要起始原料 Ethyl Chloroformate And N-Methyl Desloratadine
31251-41-9 = 79794-75-5 反应条件:1.1 Reagents: Zinc Catalysts: Titanium Tetrachloride Solvents: Tetrahydrofuran; 0 °C; 2.5 H,Reflux 标题:Synthesis Of Loratadine 作者:Xu,Huigang; Et Al 参考文献:Zhongguo Yiyao Gongye Zazhi 日期:2006 卷标:37(3) 页码:150-151]
170727-68-1 = 79794-75-5 反应条件:1.1 Solvents: Toluene; Rt -> 80 °C; 80 °C; 1.5 H,80 °C; 80 °C -> Rt 标题:Synthesis Of Loratidine 作者:Zheng,Xuewen; Et Al 参考文献:Guangdong Yaoxueyuan Xuebao 日期:2005 卷标:21(6) 页码:655-657]
= 79794-75-5 反应条件:1.1 Reagents: Trimethyl Phosphite1.2 Reagents: Sodium Hydride Solvents: Tetrahydrofuran2.1 Reagents: Triethylamine Catalysts: Triphenylphosphine,Palladium Diacetate Solvents: Dimethylformamide 标题:New Process For The Preparation Of Loratadine. 参考文献:Spain]
153654-16-1 = 79794-75-5 反应条件:1.1 Reagents: Sodium Hydride Solvents: Tetrahydrofuran 标题:Process For The Synthesis Of 8-Chloro-6,11-Dihydro-11-(1-Ethoxycarbonyl-4-Piperidylidene)-5H-Benzo[5,6]Cyclohepta[1,2-B]Pyridine [loratadine] 参考文献:Spain]
= 79794-75-5 反应条件:1.1 Reagents: Triethylamine Catalysts: Triphenylphosphine,Palladium Diacetate Solvents: Dimethylformamide 标题:New Process For The Preparation Of Loratadine. 参考文献:Spain]
165740-12-5 = 79794-75-5 反应条件:1.1 Reagents: Sodium Formate Catalysts: 2,4,5,6-Tetrakis(Diphenylamino)-1,3-Benzenedicarbonitrile Solvents: Dimethyl Sulfoxide; 20 H,Rt1.2 Reagents: Water; Rt 标题:Non-Innocent Radical Ion Intermediates In Photoredox Catalysis: Parallel Reduction Modes Enable Coupling Of Diverse Aryl Chlorides 作者:Chmiel,Alyah F.; Et Al 参考文献:Journal Of The American Chemical Society 日期:2021 卷标:143(29) 页码:10882-10889]
100643-71-8 + 1609-47-8 = 79794-75-5 反应条件:1.1 Reagents: Diisopropylethylamine Solvents: Dichloromethane; 5 Min,Rt1.2 2 H,Rt 标题:Loratadine And Analogues: Discovery And Preliminary Structure-Activity Relationship Of Inhibitors Of The Amino Acid Transporter B0At2 作者:Cuboni,Serena; Et Al 参考文献:Journal Of Medicinal Chemistry 日期:2014 卷标:57(22) 页码:9473-9479]
117810-66-9 = 79794-75-5 反应条件:1.1 120 °C2.1 Reagents: Sodium Hydride Solvents: Benzene 标题:Process For The Synthesis Of 8-Chloro-6,11-Dihydro-11-(1-Ethoxycarbonyl-4-Piperidylidene)-5H-Benzo[5,6]Cyclohepta[1,2-B]Pyridine [loratadine] 参考文献:Spain]
专利号:US-6608202-B1 优先权日:2001-08-21 标题:Process of synthesis of a tricyclic ketone intermediate 发明人:DORAN HENRY J; O'NEILL PAT M; WILLIAMS ROBERT P 权利人:SCHERING CORP 摘要:In one embodiment, the present invention describes the synthesis of a compound of Formula III, wherein X is halogen,and intermediates therefor from easily available starting materials by a simple route.
专利号:US-10155665-B2 优先权日:2014-11-03 标题 :Zeolite synthesis with dominant and secondary templates 发明人:LAI WENYIH FRANK; ROLLMAN NICHOLAS S; WALP JENNA L; LONERGAN WILLIAM W 权利人:LAI WENYIH FRANK; ROLLMAN NICHOLAS S; WALP JENNA L; LONERGAN WILLIAM W; EXXONMOBIL RES & ENG CO 摘要:Methods are provided for synthesis of various types of zeolites using synthesis mixtures that contain a dominant structure directing agent and one or more secondary structure directing agents. Advantageously, the secondary structure directing agents may substantially not alter the crystal structure and/or morphology of the crystals generated by a synthesis mixture in the presence of the dominant structure directing agent.
专利号:US-2025206743-A1 优先权日:2022-03-25 标 题:Tyk2 inhibitor synthesis and intermediates thereof 发明人:MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG 权利人:TAKEDA PHARMACEUTICALS CO 摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.
专利号:US-5296208-A 优先权日:1992-08-07 标 题 :Molecular sieve synthesis 发明人:LESCH DAVID A 权利人:UOP INC 摘要:In the hydrothermal synthesis of crystalline microporous molecular sieves from a reaction system containing an organic templating agent, it is found that removal of at least some of the organic reagent prior to the time the formation of crystalline product is complete results in an increased yield of the product. The removal of the organic reagent disrupts the equilibrium that is normally established in the reaction system at the selected crystallization temperature between product formation and product dissolution and shifts the reaction toward the formation of additional product before a new equilibrium can form.
专利号:US-9433935-B2 优先权日:2014-03-28 标 题 :Synthesis of framework modified ZSM-48 crystals 发明人:LAI WENYIH FRANK; ZHANG LEI 权利人:LAI WENYIH FRANK; ZHANG LEI; EXXONMOBIL RES & ENG CO 摘要:Methods are provided for synthesis ZSM-48 crystals (or other MRE framework crystals) having heteroatoms different from silicon and aluminum incorporated into the framework structure, and use of such crystals for applications such as catalytic processing of hydrocarbonaceous feeds. Examples of heteroatoms can include titanium, zirconium, and zinc.
专利号:US-5493065-A 优先权日:1993-06-16 标题:Liquid phase ethylbenzene synthesis with MCM-49 发明人:CHENG JANE C; SMITH C MORRIS; WALSH DENNIS E 权利人:MOBIL OIL CORP 摘要:There is provided a process for the liquid phase synthesis of ethylbenzene with a zeolite designated MCM-49. The process involves the alkylation of benzene with ethylene under liquid phase conditions.
1: Moukharskaya J, Abrams DM, Ashikaga T, Khan F, Schwartz J, Wilson K, Verschraegen C, Openshaw T, Valentine J, Eneman J, Unger P, Ades S. Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim. Support Care Cancer. 2016 Feb 19. [Epub ahead of print] doi: 10.3109/03639045.2015.1052078. Epub 2015 Jun 19. doi: 10.3109/10717544.2014.930759. Epub 2014 Jul 3. doi: 10.1016/j.jpba.2016.02.008. [Epub ahead of print] 6: Romeo C, Li Q, Copeland L. Severe pegfilgrastim-induced bone pain completely alleviated with loratadine: A case report. J Oncol Pharm Pract. 2015 Aug;21(4):301-4. doi: 10.1177/1078155214527858. Epub 2014 Mar 24. doi: 10.1016/j.bmcl.2015.02.037. Epub 2015 Feb 24. doi: 10.1016/j.jchromb.2014.12.033. Epub 2015 Jan 13. doi: 10.3109/02652048.2014.985340. Epub 2014 Nov 21. doi: 10.1016/j.jchromb.2014.12.008. Epub 2014 Dec 30. doi: 10.1016/j.clinph.2014.03.026. Epub 2014 Apr 12. doi: 10.3109/01480545.2014.900074. Epub 2014 Mar 18. doi: 10.1021/jm501086v. Epub 2014 Nov 7. doi: 10.1111/ijd.12590. Epub 2014 Sep 10. doi: 10.1111/jgs.12957. doi: 10.1155/2014/654632. Epub 2014 Jun 5. 17: Hancu G, Campian C, Rusu A, Mircia E, Kelemen H. Simultaneous determination of loratadine, desloratadine and cetirizine by capillary zone electrophoresis. Adv Pharm Bull. 2014;4(2):161-5. doi: 10.5681/apb.2014.024. Epub 2013 Dec 24.
合成参考文献
参考文献:10.1080/10410236.2011.569001 摘要:Faerber AE, Kreling DH. Now you see it. Now you don't: fair balance and adequate provision in advertisements for drugs before and after the switch from prescription to over-the-counter. Health Commun. 2012;27(1):66–74. doi: 10.1080/10410236.2011.569001. 摘要:Alsarra I, Khalil NY, Sultan M, Al-Ashban R, Belal F. Spectrofluorometric determination of montelukast in dosage forms and spiked human plasma. Pharmazie. 2005 Nov;60(11):823–6. 参考文献:10.1007/s00405-011-1696-6 摘要:Böhm M, Avgitidou G, El Hassan E, Mösges R. Liposomes: a new non-pharmacological therapy concept for seasonal-allergic-rhinoconjunctivitis. European Archives of Oto-Rhino-Laryngology. 2011 Jul 15;269(2):495–502. doi: 10.1007/s00405-011-1696-6. 摘要:Luo H, Yu Y, Shen Y, Zeng L, Yan N, Ke F, Fu X, Wang P, Kong W. [Changes of leukotriene D4 in nasal discharge and plasma of patients with persistent allergic rhinitis and the effects of antihistamine]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 Apr;25(8):342–6.